- Home
- AU vs ROIV Comparison
AU vs ROIV Comparison
Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | ROIV |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 21.0B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AU | ROIV |
|---|---|---|
| Price | $96.66 | $29.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $119.00 | $28.94 |
| AVG Volume (30 Days) | 1.9M | ★ 5.8M |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $38.71 | N/A |
| Revenue Next Year | $2.89 | $744.61 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.34 | $10.71 |
| 52 Week High | $129.14 | $32.79 |
Technical Indicators
Market Signals| Indicator | AU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 53.63 |
| Support Level | $89.75 | $26.95 |
| Resistance Level | $113.70 | $30.10 |
| Average True Range (ATR) | 3.62 | 1.12 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 36.09 | 39.66 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.